To determine if r-TPA can acheive recanalization in a shorter amount of time than urokinase.
- Tissue plasminogen activator (Activase®)Drug
Intervention Desc: Thrombolytic
- Urokinase (Abbokinase®)Drug
Intervention Desc: Thrombolytic agent
Randomized, comparison study.
All patients received a bolus injection of heparin immediately after CT ruled out hemorrhage, superselective catheterization of the occluded site using a microcatheter, continuous infusion of urokinase or r-TPA, an angiography at intervals of 30 minutes, and a neurological examination at 48 hours, 3 months, 6 months, and one year after treatment.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Severe deficits (such as hemiparesis or tetraparesis and inability to walk), moderate deficits (such as residual arm paresis or asymmetrical slight tetraparesis, and able to walk), mild deficits (such as slight impairment of function due to residual arm or leg paresis), and minimal deficits (such as little or no functional impairment).|